应用454测序技术评价非酒精性脂肪性肝病患者肠道菌群结构差异*

doi:10.3969/j.issn.1672-5069.2015.02.010

Abstract

Abstract: Objective To elucidate the changes of gut microbiota projects in patients with non-alcoholic fatty liver diseases（NAFLD）. Methods Fresh faecal samples from 47 NAFLD patients underwent liver biopsies and 34 health individuals were examined using bar coded 454 pyrosequencing technology. 16S DNA V3~V5 variable regions were sequenced and the operational taxonomy unit （OUT） was analyzed to evaluate the differences of microbiota projects. Results The OUT of patients with NAFLD were（88.32±28.27）,significantly lower than those in the controls[（109.65±30.65）,P<0.01）];In Phylum level,the abundance of Firmicutes had significantly increased in NAFLD patients than in the controls[（51.2±17.8）% vs.（46.4±12.8）%,P=0.048],while the abundance of Bacteroidetes had significantly reduced[（31.0±18.8）% vs.（43.3±14.4）%,P<0.01];In Class level,the abundance of Erysipelotrichi had significantly increased in NAFLD patients than in the controls [（3.2±5.1）% vs. （1.0±1.2）%,P=0.009],while the abundance of Bacteroidia had significantly decreased [（31.0±18.8）% vs.（42.3±14.0）%,P=0.004]; In Genus level, the Lactococcus[（0.0038±0.0001）%] had significantly reduced in NAFLD patients compared with controls [（0.0145±0.001）%,P=0.003];The same results were found in Prevotella Genus. However,Streptococcus had significantly increased in NAFLD patients [（1.50±0.03）%] than in controls （0.21±0.24）%,P=0.004]. Conclusions Patients with NAFLD had a lower diversity of gut microbiota projects.

Key words: Non-alcoholic fatty liver disease, Gut microbiota, Bar coded 454 pyrosequencing

Shen Feng, Chen Jianneng, Zheng Ruidan, et al.. Constitutional variation of gut microbiota detected by bar coded 454 pyrosequencing technology in patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 145-149.

References

[1] Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50（1）:204-210.
[2] Turnbaugh PJ,Ley RE,Hamady M,et al. The human microbiome project. Nature,2007,449（7164）: 804-810.
[3] 沈峰,范建高. 肠道菌群及宏基因组学与非酒精性脂肪性肝病研究现状. 中华肝脏病杂志,2013,21（11）：811-814.
[4] Le CE,Nielsen T,Qin J,et al. Richness of human gut microbiome correlates with metabolic markers. Nature,2013,500（7464）:541-546.
[5] 非酒精性脂肪性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志,2010,18（3）：163-166.
[6] Karlas T,Petroff D,Garnov N,et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One,2014,9（3）:e91987.
[7] Kleiner DE,Brunt EM,Van Natta M,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology,2005,41（6）:1313-1321.
[8] Schloss PD,Westcott SL,Ryabin T,et al. Introducing mothur: open-source,platform-independent,community-supported software for describing and comparing microbial communities. Appl Environ Microbiol,2009,75（23）:7537-7541.
[9] Ley RE,Turnbaugh PJ,Klein S,et al. Microbial ecology:human gut microbes associated with obesity. Nature,2006,444（7122）: 1022-1023.
[10] Turnbaugh PJ,Ley RE,Mahowald MA,et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature,2006,444（7122）:1027-1031.
[11] Larsen N,Vogensen FK,van den Berg FW,et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One,2010,5（2）:e9085.
[12] Turnbaugh PJ,Hamady M,Yatsunenko T,et al. A core gut microbiome in obese and lean twins. Nature,2009,457（7228）:480-484.
[13] Ruiz AG,Casafont F,Crespo J,et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients:evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg,2007,17（10）:1374-1380.
[14] Shanab AA,Scully P,Crosbie O,et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci,56（5）:1524-1534.
[15] Dumas ME,Barton R H,Toye A,et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A,2006,103（33）:12511-12516.
[16] Cope K,Risby T,Diehl AM. Increased gastrointestinal ethanol production in obese mice:implications for fatty liver disease pathogenesis. Gastroenterology,2000,119（5）:1340-1347.
[17] Soza A,Riquelme A,Gonzalez R,et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci,2005,50（6）:1136-1140.
[18] Kelishadi R,Farajian S,Mirlohi M. Probiotics as a novel treatment for non-alcoholic fatty liver disease;a systematic review on the current evidences. Hepat Mon,2013,13（4）:e7233.

Constitutional variation of gut microbiota detected by bar coded 454 pyrosequencing technology in patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[2]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[3]	Fu Liang, Wu Dongbing, Ji Xinzun. Application of ARFI quantification in the evaluation of liver injuries in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 377-380.
[4]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[5]	Su Shuting, Zhong Yan, Mi Yuqiang.. Management of patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 293-296.
[6]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[7]	Song Na, Liu Xiaoyan, Liu Chang, et al.. Changes of plasma thyrotropin levels in patients with nonalcoholic fatty liver disease and type 2 diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 65-68.
[8]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[9]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[10]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[11]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[12]	Xie Zhanfeng, Jia Jizhen, Zhao Shufang. Combination of notoginseng total saponin and silybin in treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 623-624.
[13]	Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.
[14]	Zhao Wentao, Cao Gaofeng, Jiao Xiaohong, et al. Efficacy of puerarin combined with metformin in the treatment of patients with non-alcoholic fatty liver disease and prediabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 409-412.
[15]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.